1. Search Result
Search Result
Results for "

HER2-targeting peptide

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

6

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P10792

    EGFR Cancer
    HER2-targeted peptide H6F is a HER2 targeting peptide that binds to HER2 to target breast cancer cells, with the amino acid sequence YLFFVFER. The HER2-targeted peptide H6F can be conjugated with the bifunctional chelating agent hydrazinonicotinamide (HYNIC) for radiolabeling with 99mTc. Single-photon emission computed tomography (SPECT) imaging shows that the labeled HER2-targeted peptide H6F specifically accumulates in HER2-positive MDA-MBA-453 tumor-bearing mice models. The HER2-targeted peptide H6F can be used for tumor molecular imaging studies .
    HER2-targeted peptide H6F
  • HY-P10648

    HER2-targeting peptide

    EGFR Cancer
    Herceptide (HER2-targeting peptide) is a HER2-targeting peptide, and can be further conjugated to the near-infrared fluorescent dye indocyanine green (HY-D0711) (ICG) for developing theranostic agents .
    Herceptide
  • HY-176976

    Drug-Linker Conjugates for ADC Cancer
    Exatecan-mpGNNG (Compound 10a) is the linker-payload component of an antibody-drug conjugate (ADC). Exatecan-mpGNNG is composed of Exatecan (HY-13631), a potent topoisomerase I inhibitor, and the linker .
    Exatecan-mpGNNG
  • HY-P11760

    EGFR Cancer
    HER2-targeted peptide H10 is a HER2-targeting peptide with a Kd value of 30.4 nM. HER2-targeted peptide H10 specifically accumulates in HER2-positive tumor tissues of xenograft mice, when conjugated with nanoparticles. HER2-targeted peptide H10 can be used for studies related to HER2-positive breast cancer .
    HER2-targeted peptide H10
  • HY-P11761

    EGFR Cancer
    HYNIC-H10F is a conjugate of HER2-targeting peptide H10F and bifunctional chelator HYNIC. HYNIC-H10F can be used in breast cancer-related research .
    HYNIC-H10F
  • HY-P11613

    EGFR Cancer
    DOTA-WC8 is a HER2-targeting peptide probe with a KD of 61.20 nM. 68Ga-labeled DOTA-WC8 serves as a PET imaging agent for the specific identification of HER2-positive breast cancer. DOTA-WC8 is applicable to breast cancer-related research .
    DOTA-WC8
  • HY-P11590

    EGFR Cancer
    WGYRGFYC (WC8) is a selective HER2-targeting peptide that binds specifically to HER2 by mimicking the antigen-binding site of trastuzumab. The DOTA precursor of WGYRGFYC has a KD of 61.20 nM for HER2. WGYRGFYC enables specific and highly sensitive detection of HER2 expression in HER2-positive breast cancer cells and tumor tissues, and monitors the dynamic downregulation of HER2 expression. WGYRGFYC rapidly distributes to target tissues and is efficiently cleared from non-target tissues via the kidneys, generating an ideal tumor-to-background ratio in imaging; it is a component of the PET radiotracer Ga-DOTA-WC8. WGYRGFYC exhibits no significant cytotoxicity in breast cancer cells, and can be used for non-invasive imaging diagnosis and therapeutic efficacy evaluation of HER2-positive breast cancer .
    WGYRGFYC

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: